Ajanta Pharma Limited promoter, Ravi Agrawal (Trustee Ravi Agrawal Trust), has announced the creation of a pledge on 2,20,000 equity shares and the release of a pledge on 2,60,000 equity shares. The creation of the pledge was for Re-Financing purposes, while the release was due to Excess Pledge. These disclosures were made on June 1, 2026, in compliance with SEBI (SAST) Regulations, 2011.
Promoter Pledge Update for Ajanta Pharma Limited
Ravi Agrawal, acting as the trustee for the Ravi Agrawal Trust and a promoter of Ajanta Pharma Limited, has officially disclosed significant adjustments to his pledged equity holdings. The announcement, dated June 1, 2026, details both the creation of new pledges and the release of existing ones, in line with the requirements of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Key Pledge Transactions
As per the disclosure, Ravi Agrawal has created a pledge on a total of 2,20,000 equity shares of Ajanta Pharma Limited. Concurrently, a pledge has been released on 2,60,000 equity shares of the company. The primary reason cited for the creation of the new pledge is Re-Financing. The release of the pledge was attributed to an Excess Pledge situation.
Details of Encumbrance and Release
The formal disclosure format provides further specifics on these transactions. For the Ravi Agrawal Trust, specifically Ravi P. Agrawal, a pledge release occurred on May 27, 2026, involving 6,063,920 shares (4.85% of total share capital). This release was part of a business financing arrangement. Following this release, the post-event holding of encumbered shares stands at 5,903,920 shares (4.73%).
Additionally, a pledge creation event was reported for Ravi P. Agrawal on May 29, 2026, involving 220,000 shares (0.18% of total share capital), also linked to business financing. The entity in whose favor this pledge was created is THE South Indian Bank Ltd, with Barclays Securities (India) Private Limited acting as the DP.
The document also lists details for other promoters and PACs, though the primary focus of the accompanying letter is on Ravi Agrawal’s transactions. For instance, Ravi P. Agrawal himself holds 285,000 shares (0.23%), and Aayush M. Agrawal, trustee of Aayush Agrawal Trust, has a holding of 14,112,924 shares (11.30%) with 8,589,162 shares (6.87%) already encumbered.
Regulatory Compliance
The disclosures, including the prescribed form detailing the creation and release of pledges on Ajanta Pharma Limited shares, have been submitted to both the BSE Limited and the National Stock Exchange of India. The company secretary of Ajanta Pharma Limited has also been copied on this communication. This reporting aligns with the requirements outlined in Regulation 31(1) and 31(2) of the SEBI (SAST) Regulations, 2011.
Source: BSE
